<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001978'>Extramedullary hematopoiesis</z:hpo> (<z:mp ids='MP_0000240'>EMH</z:mp>) in the spleen is a characteristic feature of the <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPDs</z:e>) and various other neoplastic or reactive myeloid conditions </plain></SENT>
<SENT sid="1" pm="."><plain>However, the origin of these hematopoietic precursor cells and the molecular mechanisms underlying their development in the spleen is uncertain </plain></SENT>
<SENT sid="2" pm="."><plain>The V617F mutation in the Janus Kinase 2 gene (JAK2(V617F)) was recently shown to be frequently and preferentially present in the peripheral blood and bone marrow cells of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> patients, and the resulting dysregulation of its downstream targets is important to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> pathogenesis </plain></SENT>
<SENT sid="3" pm="."><plain>To determine the occurrence and potential role of JAK2(V617F) in splenic <z:mp ids='MP_0000240'>EMH</z:mp> cells, we studied splenectomy specimens from 47 patients with significant <z:mp ids='MP_0000240'>EMH</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>JAK2(V617F) was detected by real-time PCR melting curve analysis in 22 specimens, including 11/17 <z:hpo ids='HP_0011010'>chronic</z:hpo> idiopathic <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, 7/7 <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera, 1/1 essential <z:e sem="disease" ids="C0836924" disease_type="Disease or Syndrome" abbrv="">thrombocythemia</z:e>, 1/3 CMPD unclassifiable, 1/5 <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 0/5 <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, 1/3 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and 0/6 <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> cases, whereas only the JAK2 <z:mp ids='MP_0002169'>wild-type</z:mp> allele was detected in the other 25 </plain></SENT>
<SENT sid="5" pm="."><plain>Nineteen of 20 cases with adequate bone marrow samples available for molecular examination demonstrated concordant JAK2 genotypes </plain></SENT>
<SENT sid="6" pm="."><plain>Laser-capture microdissection was then used to enrich the <z:mp ids='MP_0000240'>EMH</z:mp> and non-<z:mp ids='MP_0000240'>EMH</z:mp> splenic cell fractions, confirming that the mutant alleles specifically originated from the <z:mp ids='MP_0000240'>EMH</z:mp> cells </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, megakaryocytes in the JAK2(V617F)-positive splenectomy specimens expressed higher levels of Bcl-xL, an antiapoptotic protein and downstream target of the JAK2/STAT5 pathway </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, JAK2(V617F) is frequently present in splenic <z:mp ids='MP_0000240'>EMH</z:mp> cells associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e>, but it is rarely identified in splenic <z:mp ids='MP_0000240'>EMH</z:mp> cells associated with other myeloid disorders </plain></SENT>
<SENT sid="9" pm="."><plain>Our results indicate that the precursor cells leading to extramedullary hematopoietic expansion in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> most likely originate from the transformed bone marrow clone </plain></SENT>
<SENT sid="10" pm="."><plain>Also, dysregulation of downstream pathways such as Bcl-xL may be important to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMPD</z:e> disease pathogenesis in the spleen </plain></SENT>
</text></document>